SCHEMBL8512914

SCHEMBL8512914

Ic1c(OCc2ccccc2)ccc2c1nnn2CC1CC1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 15/20 0.50
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39
TDO2 P48775 1/20 0.38
MAPK14 Q16539 1/20 0.38
BRD4 O60885 1/20 0.37
CYP2D6 P10635 1/20 0.37
HRH1 P35367 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8509723 0.83 GRM2 (0.53) GRM2HTR2AHTR2CSLC6A4TDO2
SCHEMBL8512798 0.76 GRM2 (0.49) GRM2SLC6A4CYP2D6
SCHEMBL9604420 0.76 GRM2 (0.57) GRM2TDO2
SCHEMBL8514197 0.75 GRM2 (0.48) GRM2SLC6A4
SCHEMBL8513118 0.75 GRM2 (0.40) GRM2SLC6A4MAPK14BRD4
SCHEMBL8513414 0.73 GRM2 (0.46) GRM2TDO2
SCHEMBL8509698 0.73 GRM2 (0.55) GRM2HTR2CSLC6A4
SCHEMBL8511766 0.73 GRM2 (0.54) GRM2TDO2
SCHEMBL8513657 0.72 GRM2 (0.53) GRM2TDO2
SCHEMBL8511863 0.72 GRM2 (0.50) GRM2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2705024-B1 Alkyne benzotriazole derivatives MERCK SHARP & DOHME (US) 2015-12-16 EP disclosed
US-9139576-B2 Aminomethyl biaryl benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-09-22 US disclosed
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 US disclosed
US-8785482-B2 Cyclohexene benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2014-07-22 US disclosed
US-8785481-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2014-07-22 US disclosed
US-8772276-B2 Alkyne benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2014-07-08 US disclosed
US-20140088150-A1 CYCLOHEXENE BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2014-03-27 US disclosed
US-20140088151-A1 ALHYDROXYMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME CORP. 2014-03-27 US disclosed
US-20140088112-A1 ALKYNE BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2014-03-27 US disclosed
EP-2705025-A1 HYDROXYMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2014-03-12 EP disclosed
EP-2704574-A1 CYCLOHEXENE BENZOTRIAZOLE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2014-03-12 EP disclosed
EP-2705024-A1 ALKYNE BENZOTRIAZOLE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2014-03-12 EP disclosed
EP-2704573-A1 AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2014-03-12 EP disclosed
US-20140066443-A1 AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2014-03-06 US disclosed
WO-2012151139-A1 ALKYNE BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-11-08 WO disclosed
WO-2012151140-A1 HYDROXYMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-11-08 WO disclosed
WO-2012151138-A1 CYCLOHEXENE BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-11-08 WO disclosed
WO-2012151136-A1 AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-11-08 WO disclosed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed
US-20120135977-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088150-A1 CYCLOHEXENE BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRIK2 GRM2 1/4885HTR2A 93/4885HTR2C 91/4885
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRIK2 GRM2 1/4885HTR2A 179/4885HTR2C 130/4885
US-20120135977-A1 ETHER BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRIK2 GRM2 1/4885HTR2A 179/4885HTR2C 130/4885
US-20140066443-A1 AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES GRM2, GRM3, GRIN2C GRM2 1/4885HTR2A 80/4885HTR2C 76/4885
US-20140088112-A1 ALKYNE BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRM3 GRM2 1/4885HTR2A 93/4885HTR2C 88/4885
US-20140088151-A1 ALHYDROXYMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRM3 GRM2 1/4885HTR2A 125/4885HTR2C 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.